ImCheck Therapeutics is driving innovation in immune system modulation based on our unique know-how in the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules. We are designing the next generation of immunotherapeutic antibodies for the treatment of cancer, infectious disease, and autoimmune disease.
ICT01 in Science Translational Medicine
ImCheck Therapeutics published on Oct 20, 2021, the development results of its first-in-class cancer immunotherapeutic ICT01 in the medical journal Science Translational Medicine
Latest news
ImCheck Provides Promising Updated Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at SITC Meeting 2021
Science & Medicine
Read more ImCheck Publishes Comprehensive Overview of the Development Results of Its First-in-class Cancer Immunotherapeutic Targeting BTN3A to Activate Gamma-delta T Cells in Science Translational Medicine
Science & Medicine
Read more ImCheck to Present Updated Patient Response Data from the EVICTION Trial and Additional ICT01 Results at the SITC Annual Meeting 2021
Science & Medicine
Read more 
STAY IN TOUCH WITH OUR LATEST NEWS
Subscribe to receive our press releases and related news